Jamilu Rubin - EQRx Chief Officer
| EQRXDelisted Stock | USD 1.83 0.13 6.63% |
Insider
Jamilu Rubin is Chief Officer of EQRx Inc
| Age | 59 |
| Phone | 617 315 2255 |
| Web | https://www.eqrx.com |
EQRx Management Efficiency
The company has return on total asset (ROA) of (0.1379) % which means that it has lost $0.1379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2025) %, meaning that it created substantial loss on money invested by shareholders. EQRx's management efficiency ratios could be used to measure how well EQRx manages its routine affairs as well as how well it operates its assets and liabilities.EQRx Inc currently holds 3.83 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. EQRx Inc has a current ratio of 28.18, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about EQRx's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Wei MD | Erasca Inc | 54 | |
| Thomas Catinazzo | Relay Therapeutics | 47 | |
| Vijay Sabesan | Kymera Therapeutics | 52 | |
| Dawn Kalmar | Stoke Therapeutics | 46 | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| Lisa TesvichBonora | Erasca Inc | N/A | |
| Christopher MSc | Keros Therapeutics | 50 | |
| Richard Goold | Lyell Immunopharma | 64 | |
| JD Esq | Black Diamond Therapeutics | 59 | |
| Melissa Brody | Kymera Therapeutics | N/A | |
| Mike Ouimette | Pliant Therapeutics | 51 | |
| CPA CPA | Arvinas | 52 | |
| Gary Lee | Lyell Immunopharma | 47 | |
| Michael Fischbach | Revolution Medicines | 43 | |
| Brittany Mccleery | Sana Biotechnology | N/A | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Jack Anders | Revolution Medicines | 47 | |
| Tracey Esq | Blueprint Medicines Corp | 56 | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Michael Diem | Century Therapeutics | 53 | |
Management Performance
| Return On Equity | -0.2 | |||
| Return On Asset | -0.14 |
EQRx Inc Leadership Team
Elected by the shareholders, the EQRx's board of directors comprises two types of representatives: EQRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EQRx. The board's role is to monitor EQRx's management team and ensure that shareholders' interests are well served. EQRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EQRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Hoey, Chief Operations | ||
| Robert LLB, CoFounder Advisor | ||
| Alexis AM, Founder Directors | ||
| MAPP MD, CoFounder Advisor | ||
| Jamilu Rubin, Chief Officer | ||
| Sir CBE, CoFounder Advisor | ||
| Rona Anhalt, Chief Officer | ||
| Eric MD, Chief Exec | ||
| Melanie Nallicheri, CEO Director | ||
| Dina JD, Gen Sec |
EQRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EQRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | (75.06 M) | |||
| Shares Outstanding | 487.7 M | |||
| Shares Owned By Insiders | 11.13 % | |||
| Shares Owned By Institutions | 68.24 % | |||
| Number Of Shares Shorted | 11.3 M | |||
| Price To Book | 1.00 X | |||
| EBITDA | (517.58 M) | |||
| Net Income | (169.09 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in EQRx Stock
If you are still planning to invest in EQRx Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EQRx's history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |